
    
      Prospective, open-labeled study of 7patients with overt Type II diabetic nephropathy and >500
      mg/gm UP/Cr ratio that will mnmnmnn be randomized to maximal RAAS blockade alone or in
      combinatio (25 mg) for 2months. An analysis of the change in 1months and change in eGFR
      a2months will be performed
    
  